Abstract
Interindividual variability in xenobiotic metabolism and drug response is extensive. Genetic factors are predicted to account for 15–30% of this variability in general, but for certain drugs the genetic factor is the major determinant for outcome of drug therapy. Of particular importance for drug metabolism, drug response, and adverse drug reactions are the cytochrome P450 (CYP) enzymes, many of which are polymorphic. An essential basis for research and applications regarding interindividual variability in xenobiotic metabolism and toxicity by polymorphic CYPs is to have a common nomenclature for genetic variants and a system that allows researchers to be rapidly updated within the field. Since 1999 this has been achieved by the operation of the Human Cytochrome P450 Allele Nomenclature Committee Web site (http://www.imm.ki.se/CYPalleles/), where novel allelic variants are published after peer review. Currently, this Web site covers the nomenclature for polymorphic alleles of 22 CYP isoforms including more than 200 functionally different variants. Each CYP has its own Web page, which lists the alleles with their nucleotide changes, their functional consequences, and links to publications where the allele has been identified and characterized. The CYP allele Web site offers a rapid on-line publication of new alleles, provides an overview of peer-reviewed data, and serves as a form of quality control on research on new alleles.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Weinshilboum, R. (2003) Inheritance and drug response. N. Engl. J. Med. 348, 529–537.
Ingelman-Sundberg, M. (2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends. Pharmacol. Sci. 25, 193–200.
Kirchheiner, J., Nickchen, K., Bauer, M., et al. (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9, 442–473.
Lazarou, J., Pomeranz, B. H., and Corey, P. N. (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200–1205.
Physicians Desk Reference, 57th Edition (2003) Thomson-Delmar, Clifton Park, NY.
Pirmohamed, M., James, S., Meakin, S., et al. (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 329, 15–19.
Mjorndal, T., Boman, M. D., Hagg, S., et al. (2002) Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol. Drug Saf. 11, 65–72.
Marshall, A. (1997) Getting the right drug into the right patient. Nat. Biotechnol. 15, 1249–1252.
Nelson, D. R., Zeldin, D. C., Hoffman, S. M., Maltais, L. J., Wain, H. M., and Nebert, D. W. (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14, 1–18.
Bertz, R. J. and Granneman, G. R. (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32, 210–258.
Evans, W. E. and Relling, M. V. (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487–491.
Pirmohamed, M., and Park, B. K. (2001) Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 22, 298–305.
Ingelman-Sundberg, M., Oscarson, M., and McLellan, R. A. (1999) Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci. 20, 342–349.
Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., and Sadee, W. (2001) Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286, 2270–2279.
Shows, T. B., McAlpine, P. J., Boucheix, C., et al. (1987) Guidelines for human gene nomenclature: an international system for human gene nomenclature (ISGN, 1987). Cytogenet. Cell Genet. 46, 11–28.
Daly, A. K., Brockmoller, J., Broly, F., et al. (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6, 193–201.
Antonarakis, S. E. (1998) Recommendations for a nomenclature system for human gene mutations: Nomenclature Working Group. Hum. Mutat. 11, 1–3.
den Dunnen, J. T. and Antonarakis, S. E. (2001) Nomenclature for the description of human sequence variations. Hum. Genet. 109, 121–124.
Ingelman-Sundberg, M., Daly, A. K., Oscarson, M., and Nebert, D. W. (2000) Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles. Pharmacogenetics 10, 91–93.
Ingelman-Sundberg, M., Oscarson, M., Daly, A. K., Garte, S., and Nebert, D. W. (2001) Human cytochrome P-450 (CYP) genes: a web page for the nomenclature of alleles. Cancer Epidemiol. Biomarkers Prev. 10, 1307–1308.
Acknowledgments
We gratefully acknowledge the editorial and advisory boards of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee Web site, as well as Dr. Mikael Oscarson for his long-lasting and high-quality work in developing and establishing this Web site.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc.
About this protocol
Cite this protocol
Sim, S.C., Ingelman-Sundberg, M. (2006). The Human Cytochrome P450 Allele Nomenclature Committee Web Site. In: Phillips, I.R., Shephard, E.A. (eds) Cytochrome P450 Protocols. Methods in Molecular Biology, vol 320. Humana Press, Totowa, NJ. https://doi.org/10.1385/1-59259-998-2:183
Download citation
DOI: https://doi.org/10.1385/1-59259-998-2:183
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-58829-441-8
Online ISBN: 978-1-59259-998-1
eBook Packages: Springer Protocols